Efficacy of teriparatide compared with risedronate on FRAX(®)-defined major osteoporotic fractures: results of the VERO clinical trial

SUMMARY: FRAX(®) calculates the 10-year probability of major osteoporotic fractures (MOF), which are considered to have a greater clinical impact than other fractures. Our results suggest that, in postmenopausal women with severe osteoporosis, those treated with teriparatide had a 60% lower risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Body, J.-J., Marin, F., Kendler, D.L., Zerbini, C.A.F., López-Romero, P., Möricke, R., Casado, E., Fahrleitner-Pammer, A., Stepan, J.J., Lespessailles, E., Minisola, S., Geusens, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497508/
https://www.ncbi.nlm.nih.gov/pubmed/32474650
http://dx.doi.org/10.1007/s00198-020-05463-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497508/
https://www.ncbi.nlm.nih.gov/pubmed/32474650
http://dx.doi.org/10.1007/s00198-020-05463-4

Ejemplares similares